{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:47:46Z","timestamp":1781552866358,"version":"3.54.5"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2023,3]]},"abstract":"Zusammenfassung<\/jats:title>\n Ziel der Studie In den letzten Jahren konnten Studien, in denen die\n Verwendung von Psilocybin zur Behandlung psychischer St\u00f6rungen\n untersucht wurde, vielversprechende Ergebnisse zeigen. Vor diesem Hintergrund\n wurden Einstellungen von ausgebildeten Psychiater*innen und\n Psychotherapeut*innen zu Psilocybin und Psilocybin-unterst\u00fctzten\n Therapien untersucht.<\/jats:p>\n Methodik Eine Online-Befragung ergab 530 g\u00fcltige Teilnahmen von\n Personen mit geeignetem Berufsprofil. In der statistischen Auswertung konnten\n relevante Pr\u00e4diktoren f\u00fcr Einstellungsma\u00dfe ermittelt\n werden.<\/jats:p>\n Ergebnisse Die Meinungen von Expert*innen auf dem Gebiet der\n Behandlung psychischer St\u00f6rungen bez\u00fcglich Psilocybin und\n Psilocybin-unterst\u00fctzten Therapien sind geteilt und der Kenntnisstand\n der Befragten teilweise noch gering. Ein gro\u00dfer Teil der Befragten\n h\u00e4lt die Behandlung psychischer St\u00f6rungen mit Psilocybin\n f\u00fcr vielversprechend. Eine Behandlung von Depressionen mit Psilocybin\n wird von der Mehrheit der Teilnehmenden als vielversprechend\n eingesch\u00e4tzt. Die Ergebnisse weisen darauf hin, dass ein h\u00f6herer\n Kenntnisstand \u00fcber Psilocybin mit optimistischeren Sichtweisen\n bez\u00fcglich einer Verwendung von Psilocybin in einem therapeutischen\n Rahmen zusammenh\u00e4ngt. Zus\u00e4tzlich pr\u00e4sentierte\n wissenschaftliche Informationen \u00fcber den aktuellen Forschungsstand zur\n Thematik f\u00fchren teilweise zu optimistischeren Einstellungen \u00fcber\n Psilocybin und einer Verwendung von Psilocybin in der Behandlung psychischer\n St\u00f6rungen.<\/jats:p>\n Schlussfolgerung Sollte der Psilocybin betreffende wissenschaftliche und\n \u00f6ffentliche Diskurs in Zukunft weiter wachsen, sind auch\n Einstellungs\u00e4nderungen der Psychotherapeut*innen und\n Psychiater*innen zu erwarten.<\/jats:p>","DOI":"10.1055\/a-1846-1161","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T22:57:06Z","timestamp":1655765826000},"page":"80-87","source":"Crossref","is-referenced-by-count":4,"title":["Einstellungen von Expertinnen und Experten f\u00fcr psychische\n Gesundheit gegen\u00fcber Psilocybin"],"prefix":"10.1055","volume":"91","author":[{"given":"Christopher","family":"Schmidt","sequence":"additional","affiliation":[{"name":"MIND Foundation, Berlin, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Jungaberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"M W Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"100538","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor\n men: An open-label safety and feasibility pilot study","volume":"27","author":"B T Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept\n study","volume":"29","author":"M P Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an\n open-label feasibility study","volume":"3","author":"R L Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and\n anxiety in patients with life-threatening cancer: A randomized double-blind\n trial","volume":"30","author":"R R Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco\n addiction","volume":"28","author":"M W Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"R Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A\n Randomized Clinical Trial","volume":"78","author":"A K Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"M W Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eurpsy.2005.04.008","article-title":"Hallucinogen persisting perception disorder after psilocybin consumption: a case\n study","volume":"20","author":"M-L Espiard","year":"2005","journal-title":"Eur Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/2045125312451270","article-title":"Hallucinogen-persisting perception disorder","volume":"2","author":"L Hermle","year":"2012","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the\n management of mood, anxiety, and substance-use disorders: a systematic review of\n systematic reviews","volume":"11","author":"R G Dos Santos","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"DE Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the\n Controlled Substances Act","volume":"142","author":"M W Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/NMD.0000000000000828","article-title":"A survey of American psychiatrists' attitudes toward classic\n hallucinogens","volume":"206","author":"B S Barnett","year":"2018","journal-title":"J Nerv Ment Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2307\/2685594","article-title":"Using heteroscedasticity consistent standard errors in the linear regression\n model","volume":"54","author":"J S Long","year":"2000","journal-title":"Am Stat"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/0269881115581980","article-title":"European rating of drug harms","volume":"29","author":"J van Amsterdam","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","article-title":"Harm potential of magic mushroom use: a review","volume":"59","author":"J van Amsterdam","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.nsa.2022.100104","article-title":"Methodological challenges in psychedelic drug trials: Efficacy and safety of\n psilocybin in treatment-resistant major depression (EPIsoDE) \u2013 Rationale\n and study design","volume":"1","author":"L J Mertens","year":"2022","journal-title":"Neuroscience Applied"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1846-1161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T20:34:09Z","timestamp":1719520449000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1846-1161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":19,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,3,14]]},"published-print":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1846-1161","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]}}}